← Back to Search

Soluble Fiber Supplement

Inulin for Non-alcoholic Fatty Liver Disease (MILE Trial)

N/A
Waitlist Available
Led By Karen Corbin, PhD
Research Sponsored by AdventHealth Translational Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

MILE Trial Summary

This trial will test whether feeding the gut bacteria soluble fiber will help decrease liver fat in obese individuals.

MILE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute Change in Liver Fat

MILE Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: InulinActive Control1 Intervention
Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.

Find a Location

Who is running the clinical trial?

AdventHealth Translational Research InstituteLead Sponsor
48 Previous Clinical Trials
20,124 Total Patients Enrolled
3 Trials studying Non-alcoholic Fatty Liver Disease
1,302 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Translational Research Institute for Metabolism and Diabetes, FloridaLead Sponsor
40 Previous Clinical Trials
3,540 Total Patients Enrolled
2 Trials studying Non-alcoholic Fatty Liver Disease
1,264 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Karen Corbin, PhDPrincipal InvestigatorStudy Principal Investigator

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
MetabolismJournal
Non-alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease
Lonardo, Amedeo, Silvia Sookoian, Carlos J. Pirola, and Giovanni Targher. 2016. “Non-alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease”. Metabolism. Elsevier BV. doi:10.1016/j.metabol.2015.09.017.
European Journal of NutritionJournal
Lack of Liver Steatosis in Germ-free Mice Following Hypercaloric Diets
Kaden-Volynets, Valentina, Marijana Basic, Ulrike Neumann, Dominik Pretz, Andreas Rings, André Bleich, and Stephan C. Bischoff. 2018. “Lack of Liver Steatosis in Germ-free Mice Following Hypercaloric Diets”. European Journal of Nutrition. Springer Science and Business Media LLC. doi:10.1007/s00394-018-1748-4.
JamaJournal
Nonalcoholic Fatty Liver Disease
Rinella, Mary E.. 2015. “Nonalcoholic Fatty Liver Disease”. Jama. American Medical Association (AMA). doi:10.1001/jama.2015.5370.
American Journal of GastroenterologyJournal
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients with Diabetes: A Community-based Cohort Study
Adams, Leon A, Scott Harmsen, Jennifer L St. Sauver, Phunchai Charatcharoenwitthaya, Felicity B Enders, Terry Therneau, and Paul Angulo. 2010. “Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients with Diabetes: A Community-based Cohort Study”. American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health). doi:10.1038/ajg.2010.18.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top